S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer

Part of paid clinical trials in San Antonio, Texas.

Sponsor
National Cancer Institute (NCI)
Study ID
NCT00087412
Phase
PHASE2
Status
Completed

Conditions

  • Adenocarcinoma of the Lung
  • Large Cell Lung Cancer
  • Recurrent Non-small Cell Lung Cancer
  • Squamous Cell Lung Cancer
  • Stage IIIB Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial is studying how well erlotinib works in treating patients with advanced primary non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth

Key Dates

First listed
Jul 12, 2004
Start date
Sep 30, 2004
Status verified
Feb 2013
Primary completion
Jul 31, 2007

Study Design

Enrollment
65 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Patients receive oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Median survival [ Time Frame: Up to 3 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Southwest Oncology GroupSan AntonioTexas78245-

Find similar trials in San Antonio, TX

By research site
Southwest Oncology Group· San Antonio, TX

Related Studies